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Abstract
Introduction: The culture-independent serum (1®3)-b-D-glucan (BG) detection test may allow early diagnosis of
invasive fungal disease, but its clinical usefulness needs to be firmly established. A prospective single-center
observational study was conducted to compare the diagnostic value of BG assay, Candida score (CS), and
colonization index in intensive care unit (ICU) patients at risk for Candida sepsis.
Methods: Of 377 patients, consecutively admitted to ICU for sepsis, 95 patients having an ICU stay of more than
five days were studied. Blood specimens for fungal culture and BG measurement were obtained at the onset of
clinical sepsis. For CS and colonization index calculations, surveillance cultures for Candida growth, and/or clinical
data were recorded.
Results: Sixteen (16.8%) patients were diagnosed with proven invasive fungal infection, 14 with candidiasis (13
candidemia and 1 mediastinitis) and 2 with pulmonary aspergillosis or fusariosis. Of 14 invasive Candida-infection
patients, 13 had a serum sample positive for BG, 10 had a CS value ≥3, and 7 a colonization index ≥0.5. In the 12
candidemic patients, a positive BG result was obtained 24 to 72 hrs before a culture-documented diagnosis of
invasive candidiasis. The positive and negative predictive values for the BG assay were higher than those of CS and
colonization index (72.2% versus 57.1% and 27.3%; and 98.7% versus 97.2% and 91.7%, respectively).
Conclusions: A single-point BG assay based on a blood sample drawn at the sepsis onset, alone or in combination
withCS, may guide the decision to start antifungal therapy early in patients at risk for Candida infection.
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Introduction
Invasive candidiasis (IC) in non-neutropenic patients
admitted to the intensive care unit (ICU) is a serious
problem [1-3] and, of particular concern, associated
with high mortality [4], especially when prompt and
adequate antifungal treatment is not administered [5-8].
Furthermore, outcome is dependent on the causative
Candida species and management of the primary focus
of infection [9,10], and continues to be suboptimal [11].
Early identification of ICU patients with signs of sepsis
at high risk of IC is challenging due to the complexity of
the patients’ underlying conditions and low yield of fun-
gal cultures [12]. However, the timely recognition of IC
is essential to driving clinical decision processes and dic-
tating specific therapeutic strategies [13].
Measurement of the serum (1®3)-b-D-glucan (BG) is
a non-invasive testing for circulating fungal cell wall
components [14], that allows the systematic screening
and prompt identification of fungal infections (with the
exception of cryptococcosis and zygomycosis) [15]. This
test is considered an aid for the diagnosis of fungemia
and deep-seated mycoses including IC [16-18], and it
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malignancies [16,17]. BG rises before infection becomes
clinically apparent [16,17], but the high false-positive
rates [19,20] make it necessary to refine its utility as a
tool for the early diagnosis of invasive fungal infections
(IFIs) [15].
At present, only clinical prediction rules of the risk of
IC [21-23] or simpler scoring systems that differentiate
patients with Candida colonization from those with
ongoing but still occult Candida infection [24,25] are
available. Their discriminative role varies; for example, a
Candida score (CS) ≥3 was shown to select non-neutro-
penic critically ill patients at risk for IC more accurately
than the Candida colonization index [25]. Although
based on preliminary data, León et al. [26] underscored
the clinical usefulness of combining CS and serum levels
of BG to discriminate between colonization and proven
Candida infection.
The present study was conducted to compare the
diagnostic value of CS, colonization index, and the
serum BG detection in a prospective cohort of ICU
patients at risk for Candida sepsis.
Materials and methods
Patients and specimen collection
The study was conducted in an 18-bed adult ICU of a
tertiary university teaching hospital admitting approxi-
mately 900 patients per year. The local institutional
review committee approved the study, and informed
consent was waived because of the observational nature
of this study. All patients consecutively admitted to our
ICU between March and August 2010 with signs of sep-
sis [27] were eligible for enrollment in this study.
Patients were enrolled if they had stayed in the ICU for
more than five days, had not been diagnosed with and
then treated for IFI at baseline, and had a neutrophil
count ≥500/mm
3 (Figure 1).
Age, gender, Simplified Acute Physiology Score II
(SAPS II) [28] and Sequential Organ Failure Assessment
(SOFA) [29], primary diagnosis, presence of various
known risk factors for candidiasis (for example, an
indwelling venous catheter, broad-spectrum antibiotic
therapy, or treatment with corticosteroids), abdominal
surgery, and outcome were recorded. Variables poten-
tially influencing BG test results, such as renal
Figure 1 Flow chart of the study patients. ICU, intensive care unit; IFI, invasive fungal infection.
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Page 2 of 10replacement therapy, bacteremia, and recent administra-
tion of albumin, immunoglobulin products, or a b-lac-
tam antibiotic (that is, amoxicillin-clavulanic acid or
piperacillin-tazobactam) [20,30], were also recorded.
Antifungal treatment was started at the discretion of
the attending physician.
For all patients, specimens from the Candida surveil-
lance sites, such as rectum, oropharynx, skin (axillary
surface), and urinary tract, were obtained on the day of
admission to the ICU and at Days 0 and 3 following
enrollment, and once a week thereafter until discharge
from the ICU or death. Specimens for cultures from
other anatomical sites were ordered by the attending
physician, as clinically indicated. For each patient and
only at the onset of sepsis, blood specimens were simul-
taneously obtained for BG assay (from a peripheral veni-
puncture and/or an arterial line) and for culture (from a
peripheral venipuncture and/or intravascular catheter).
Blood cultures were processed using the automated
BACTEC system (Becton Dickinson Diagnostic Instru-
ments, Sparks, MD, USA).
Definitions of IFIs and Candida colonization
Proven IFI was determined on the basis of the European
Organization of the Research and Treatment of Cancer/
Mycoses Study Group (EORTC/MSG) criteria [31],
modified such that they could be applied with greater
relevance to non-neutropenic adults [32], excluding BG
detection as a microbiological criterion. Proven IC was
defined by: i) histological evidence of yeast cells or
hyphae or pseudohyphae from normally sterile site (that
is, fluid obtained by drain), ii) blood culture positive for
Candida species, or iii) positive culture result for sample
from any other sterile site (excluding urine, sputum,
bronchoalveolar lavage fluid, mucous membrane swabs,
and specimens from skin sites) [32]. Candidemia was
considered to be catheter-related if simultaneous quanti-
tative cultures showed a ratio of ≥ 5:1 in colony-forming
unit of blood samples obtained through the catheter and
a peripheral vein. Patients with proven invasive mold
infection had histological evidence of tissue invasion by
filamentous fungi, the isolation of a mold from a nor-
mally sterile but clinically infected body site (excluding
bronchoalveolar lavage fluid, a cranial sinus cavity speci-
men, and urine), or blood culture that yields a mold (for
example, Fusarium species) in the context of a consis-
tent infectious disease process [31].
Candida colonization was defined as positive culture
for fungal species from any of the above mentioned sur-
veillance sites. Colonization was considered, respectively,
unifocal or multifocal when Candida species were iso-
lated from one focus or simultaneously from various
non-contiguous foci [26]. Candiduria was defined as the
presence of at least 10
4 colony-forming units/mL of the
same Candida species [26].
CS and colonization index
The CS and colonization index were calculated when
results of the patients’ surveillance cultures, with the
exception of blood cultures, were available. The CS for a
cut-off value of 3 was as follows: total parenteral nutri-
tion × 1, plus surgery × 1, plus multifocal Candida colo-
nization × 1, plus severe sepsis × 2 [26]. The
colonization index was calculated as the ratio of the
number of culture-positive surveillance sites to the total
number of sites cultured [24]. The cut-off points for dis-
criminating between Candida species colonization and
IC were ≥3f o rt h eC Sa n d≥0.5 for the colonization
index [24,25]. For each patient, maximum values
recorded for CS and colonization index at or before the
episode of IC were used in the analysis. In the absence
of IC, the maximum of all observed values was used.
BG assay
Patients’ sera recovered from arterial and/or venous
blood specimens (see above) were tested for BG (Fungi-
tell
®; Associates of Cape Cod Inc, Falmouth¸ MA, USA)
as recommended by the manufacturer. The concentra-
tion of BG in each sample was automatically calculated
using a calibration curve with standard solutions ranging
from 31.25 to 500 pg/mL. The manufacturer’sB Gc u t -
off of 80 pg/mL was used. All samples were analyzed in
triplicate and the mean was assigned as the final result
for the specimen. Assay results were not reported to
treating clinicians.
Statistical analysis
Data were analyzed using STATA 10 (StataCorp LP,
College Station, Texas, USA). Normally distributed
continuous variables were reported as mean ± SD and
compared using Student’s t test. Medians with ranges
were used to describe non-normally distributed contin-
uous variables, and compared using the Mann-Whitney
U-test. Categorical variables were reported as percen-
tages and compared using the two-tailed c
2 test or
Fisher’s exact test, as appropriate. The following para-
meters of diagnostic performance and their 95% confi-
dence intervals (CIs) were calculated: sensitivity,
specificity, positive and negative predictive value (PPV,
NPV), and positive and negative likelihood ratios (PLR,
NLR), and Cohen’s kappa. The discriminatory powers
for BG, CS, and colonization index were evaluated by
their respective areas under the receiver operating
characteristic (ROC) curves (AUCs). ROC AUC com-
parisons were performed using the method of Hanley
and McNeil [33].
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Of 377 patients with clinical signs of sepsis admitted to
the ICU during the study period, 95 who fulfilled the
inclusion criteria above specified were enrolled as parti-
cipants (Figure 1). Characteristics of the 95 subjects (16
case patients in the IFI group and 79 patients in the
group without evidence of IFI) are shown in Table 1.
The majority of patients (74%) had at least one predis-
posing defined host (that is, use of corticosteroids or
other immunosuppressants) and/or risk factors.
Table 1 Demographics and clinical characteristics of studied groups
Total
(n = 95)
IFI
a
(n = 16)
No IFI
(n = 79)
P
Age, median years (range) 69 (18 to 93) 74 (53 to 82) 69 (18 to 93) 0.12
Male sex (%) 65 (68.4) 11 (68.8) 54 (68.4) 0.97
SAPS II, median (range) 47 (14 to 76) 49.5 (26 to 74) 46 (14 to 76) 0.18
SOFA, median (range) 6 (0 to 16) 5.5 (0 to 15) 6 (0 to 16) 0.33
ICU stay, median days (range)
Before sepsis onset 7 (6 to 67) 8.5 (6 to 34) 7 (6 to 67) 0.95
Overall 20 (6 to 180) 28 (7 to 92) 20 (6 to 180) 0.24
ICU mortality (no.,%) 23 (24.2) 6 (37.5) 17 (21.5) 0.20
Diagnosis on ICU admission (no.,%)
Medical
Surgical
Trauma
61 (64.2)
12 (12.6)
22 (23.2)
13 (81.3)
2 (12.5)
1 (6.2)
48 (60.8)
10 (12.7)
21 (26.6)
0.12
1
0.11
Multifocal Candida colonization (no.,%) 40 (42.1) 10 (62.5) 30 (37.9) 0.07
Abdominal surgery (no.,%) 11 (11.6) 2 (12.5) 9 (11.4) 1
Risk factors (no.,%)
Mechanical ventilation 85 (89.5) 16 (100) 69 (87.3) 0.20
Central venous catheter 86 (90.5) 15 (93.7) 71 (89.9) 0.63
Broad to spectrum antibiotics 71 (74.7) 14 (87.5) 57 (72.2) 0.19
Total parenteral nutrition 10 (10.5) 7 (43.7) 3 (3.8) < 0.001
Corticosteroids 8 (8.4) 3 (18.7) 5 (6.3) 0.13
Renal replacement therapy 12 (12.6) 5 (31.3) 7 (8.9) 0.03
Underlying diseases (no.,%)
COPD 20 (21.1) 5 (31.2) 15 (19.9) 0.27
Solid transplants 1 (1.1) 1 (6.3) 0 0.17
HIV 1 (1.1) 1 (6.3) 0 0.17
Solid cancer 12 (12.6) 3 (18.7) 9 (11.4) 0.40
Hematological malignancy 1 (1.1) 1 (6.3) 0 0.17
Cirrhosis 1 (1.1) 1 (6.3) 0 0.17
Chronic renal failure 24 (25.3) 8 (50.0) 16 (20.3) 0.02
Diabetes 51 (53.7) 10 (62.5) 41 (51.9) 0.44
Clinical condition (no.,%)
Severe sepsis 54 (56.8) 5 (31.2) 49 (62.0) 0.02
Septic shock 21 (22.1) 10 (62.5) 11 (13.9) < 0.001
Pneumonia 29 (30.5) 5 (31.3) 24 (30.4) 1
Gram-positive bloodstream infection
b 11 (11.5) 1 (6.2) 10 (12.6) 0.46
Gram-negative bloodstream infection
c 7 (7.4) 0 7 (8.9) 0.21
Other bacterial infection
d 15 (15.7) 3 (18.7) 12 (15.2) 0.72
No. of patients (%) with a:
Positive BG result 20 (21.1) 15 (93.7) 5 (6.3) < 0.001
CS value ≥3 21 (22.1) 12 (75.0) 9 (11.4) < 0.001
Colonization index ≥0.5 33 (35.1) 9 (56.3) 24 (30.4) 0.04
BG, (1®3)-b-D-glucan; COPD; chronic obstructive pulmonary disease; CS, Candida Score; IFI, invasive fungal infection; SAPS II, Simplified Acute Physiology Score II;
SOFA, Sequential Organ Failure Assessment;
a Two patients developed pulmonary aspergillosis or fusariosis.
b By coagulase-negative staphylococci (n = 5), Staphylocccus aureus (n = 3), Enterococcus faecalis (n = 2), or Streptococcus mitis (n = 1).
c By Klebsiella pneumoniae (n = 2), Pseudomonas aeruginosa (n = 1), Escherichia coli (n = 1), Providencia stuartii (n = 1), Enterobacter aerogenes (n = 1), or Proteus
mirabilis and P. aeruginosa (n = 1).
d Include urinary tract, wound, or fluid infections.
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identified on the basis of modified EORTC/MSG
criteria.
The overall prevalence of IFI was 16.8%. Proven cases
included 2 pulmonary mold infections (1 with Aspergil-
lus fumigatus and 1 with Fusarium solani)a n d1 4Can-
dida infections, of which 13 candidemia (10 with C.
albicans,1w i t hC. glabrata,1w i t hC. parapsilosis,a n d
1w i t hC. tropicalis) and 1 mediastinitis (with C. albi-
cans). Eighteen patients had documented bacterial
bloodstream infections (1 with and 17 without concomi-
tant IFI).
Thirteen of 95 patients (only 1 of the IFI group) were
receiving empirical antifungal therapy (7 with echino-
candin and 6 with fluconazole) two to four days before
testing.
Blood sampling for BG serum measurement
A total of 130 serum samples were tested with the BG
assay. For the first enrolled 35 patients, BG was mea-
sured in 70 paired sera from their respective venous and
arterial blood specimens, which were collected concomi-
tantly in order to assess the equivalence of measuring
BG in blood samples obtained from peripheral veni-
puncture or from arterial catheters. This is also in con-
sideration that the pre-analytical environmental
contamination by BG of the tested blood is generally
considered a major limitation of this assay.
Using the predefined cut-off value of 80 pg/mL, 10 of
35 patients had arterial and venous sera that tested as
positive for BG. For the remaining 25 patients, both the
serum specimens tested as negative for BG (range, 10 to
65 pg/mL). The BG levels obtained in the arterial and
venous specimens were not different: 355.5 ± 140.9 and
347.5 ± 148.9 pg/mL, respectively (P = 0.24). Figure 2
shows the overall test results for the 10 BG-positive
patients according to IC diagnosis. The BG level in the
true BG-positive sera (464 ± 81 pg/mL) was significantly
higher than in the false BG-positive sera (217 ± 115 pg/
mL) (P < 0.001). Since the BG assay worked well also
with the serum retrieved from non-venous blood sam-
pling, only arterial blood specimens were subsequently
used for BG determination in the other 60 study
participants.
Overall, sera from 95 patients were evaluated. Patients
with IFI were compared to patients who had no identi-
fied IFI according to the ICU-adapted EORTC/MSG cri-
teria (Table 1). Fifteen of 16 IFI patients yielded BG-
positive results. Among the patients who had no IFI,
only 5 of 79 patients tested had BG-positive results. The
sensitivity, specificity, PPV, and NPV of BG testing for
the diagnosis of IFI in all 95 patients were 93.7%, 93.6%,
75.0%, and 98.6%, respectively.
IC according to BG assay, colonization index, and CS
Fourteen of the 95 patients with BG serum level deter-
minations (Table 1) had an ongoing IC. In 13 the BG
was positive and in 1 was negative. The features of these
patients are summarized in Table 2. The mean BG level
was 436.42 ± 132.13 pg/mL, whereas the median of the
BG levels for the 14 patients was 500 (range 27 to ≥500)
pg/mL. The patient with a negative BG test had
received, four days before the serum sampling, antifun-
gal treatment with caspofungin, an antifungal drug that
interferes with BG synthesis. In all 13 patients, a positive
BG assay result was obtained 24 to 72 hrs before a posi-
tive bloodstream culture result.
A number of surveillance specimens from the 95
patients were screened for the presence of Candida spe-
cies. A colonization index ≥0.5 was found in 30.4% (24/
79) of no-IFI patients and in 56.3% (9/16) of patients
with IFI (P = 0.04) (Table 1). IC according to the coloni-
zation index occurred in 7 of 33 patients.
As shown in Table 1 the percentage of patients with
severe sepsis was significantly higher in the no-IFI
group (P = 0.02), whereas septic shock was significantly
higher in patients with IFI (P < 0.001). Total parenteral
nutrition was also significantly higher in the group of
IFI (P < 0.001). Ten of 21 patients with a CS ≥3h a da n
ongoing IC.
Diagnostic test indices for IC are presented in Table 3.
BG had better results when compared with CS and colo-
nization index in all studied variables. In particular, the
BG test gave a significantly higher number of positive
results with a sensitivity of 92.9% versus 85.7% of CS
and 64.3% of the colonization index. The specificities of
BG, CS, and colonization index were also dissimilar
(93.7%, 88.6%, and 69.7%, respectively). The areas under
the ROC curves for BG, CS, and colonization index
were 0.98 (95% CI 0.92 to 1.00), 0.80 (95% CI 0.69 to
Figure 2 (BG results of sera from two blood sampling sites for
subjects with or without IC.
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agreement between BG assay and CS was moderate
(kappa = 0.53) and that between BG assay and coloniza-
tion index was poor (kappa = 0.10).
T h ec o m b i n a t i o no fap o s i t i v eB Gr e s u l ta n daC S
value ≥3 increased the sensitivity (100% (95% CI, 76.8%
to 100%)) and NPV (100% (95% CI, 94.6% to 100%)) for
diagnosis of IC, compared to 92.9% and 97.2% for the
BG test alone, respectively. Conversely, the specificity
(83.5% (95% CI 73.5% to 90.9%)) and PPV (51.8% (95%
CI, 31.9% to 71.3%)) based on combined tests was lower
than those of the BG test (93.7% and 72.2%,
respectively).
Among the 5 patients with false-positive BG tests, 4
were treated with b-lactams and 1 was exposed to
surgical gauze, whereas 36 of the BG-negative patients
were receiving b-lactam antibiotic therapy and 4 under-
went a surgical gauze packing before BG testing.
Discussion
Using a single sample of patients obtained at the onset
of the septic syndrome in our evaluation, which
included 16 subjects with IFI and 79 with no IFI, a BG
level ≥80 pg/mL had sensitivity and specificity of 93.7%
and 93.6% for confirmed IFI, respectively. With respect
to prior studies [15,34], overall BG assay sensitivity was
higher in our cohort, likely because of lack of subjects
in the EORTC/MSG categories with inherent diagnostic
uncertainty (possible or probable IFI) and/or in whom
no active IFI occurred at the time of sampling.
Table 2 Fourteen patients with proven invasive Candida infection and their serum BG measurements before diagnosis
No. SAPS
II
Underlying conditions Clinical syndrome/
admission diagnosis
Type/source of
infection
BG level
(pg/mL)
a
Antifungal
treatment
Outcome LOS
ICU
(days)
8 35 Steroid therapy, solid cancer Respiratory failure,
severe sepsis
Candidemia/
unknown
≥500 Caspofungin Alive 30
15 48 Diabetes, obesity, chronic renal failure Septic shock Candidemia/UTI ≥500 Anidulafungin Dead 7
18 69 Chronic renal failure, diabetes Respiratory failure, septic
shock
Mediastinitis/
Unknown
≥500 Anidulafungin Dead 12
21 64 COPD Septic shock Candidemia/
unknown
≥500 Anidulafungin Alive 8
29 61 Diabetes, chronic heart failure Respiratory failure,
severe sepsis
Candidemia/UTI 480 Anidulafungin Dead 92
32 67 Chronic heart failure, solid cancer Respiratory failure Candidemia/CVC 400 Fluconazole Alive 26
35 45 Hematological malignancy, diabetes Septic shock Candidemia/
unknown
255 Anidulafungin Dead 7
51 65 AIDS, cirrhosis Septic shock, ALI Candidemia/CVC 322 Caspofungin Dead 7
57
b 59 Obesity, solid cancer Respiratory failure, septic
shock
Candidemia/CVC 27 Caspofungin Dead 14
60 39 Renal transplant, steroid therapy Trauma, severe sepsis Candidemia/CVC ≥500 Caspofungin Alive 35
74 51 Intestinal occlusion, chronic renal
failure
Respiratory failure,
severe sepsis
Candidemia/
unknown
≥500 Anidulafingin Alive 65
79 26 COPD, chronic hearth failure, diabetes Septic shock, respiratory
failure
Candidemia/CVC ≥500 Anidulafungin Alive 45
87 41 Chronic hearth failure, COPD, diabetes,
abdominal surgery
Severe sepsis, respiratory
failure
Candidemia/UTI ≥500 Caspofungin Alive 45
89 30 Chronic hearth failure, abdominal
surgery, chronic renal failure
Septic shock Candidemia/UTI ≥500 Caspofungin Alive 50
a Values of ≥500 pg/mL were converted to the 500-pg/mL ones for statistical analysis.
b This patient was empirically treated with caspofungin before BG testing.
ALI, acute lung injury; COPD; chronic obstructive pulmonary disease; CVC, central venous catheter; LOS, length of stay; SAPS II, Simplified Acute Physiology Score
II; UTI, urinary tract infection
Table 3 Performances of (1®3)-b-D-glucan assay (BG), Candida score (CS), and colonization index for detection of
invasive candidiasis in 95 patients
Sensitivity (%)
(95% CI)
Specificity (%)
(95% CI)
PPV (%)
(95% CI)
NPV (%)
(95% CI)
PLR (%)
(95% CI)
NLR (%)
(95% CI)
BG cut-off value, 80 pg/mL 92.9 (66.1 to 99.8) 93.7 (85.8 to 97.9) 72.2 (46.5 to 90.3) 98.7 (92.8 to 99.9) 14.74 (4.65 to 47.52) 0.07 (0.02 to 0.39)
CS ≥3 85.7 (57.2 to 98.2) 88.6 (79.5 to 94.7) 57.1 (34.0 to 78.2) 97.2 (90.3 to 99.7) 7.51 (2.79 to 18.29) 0.16 (0.02 to 0.54)
Colonization index ≥0.5 64.3 (35.1 to 87.2) 69.6 (58.2 to 79.5) 27.3 (13.3 to 45.5) 91.7 (81.6 to 97.2) 2.12 (0.84 to 4.25) 0.51 (0.16 to 1.11)
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was 92.9%, whereas all but five episodes of non-fungal
infections had BG concentrations higher than the cut-
off value (specificity 91.4%).
In a multicenter evaluation of the Fungitell kit con-
ducted in the United States by Ostrosky-Zeichner et al.
[35], the sensitivity of the assay for patients with proven
IC (n = 107; cut-off, 80 pg/mL) was 77.6% based on a
single sample obtained from the patient within 72 hrs
after entry into the study. A single-sample strategy was
also adopted in studies that, similarly to ours, involved
patients who had or developed systemic Candida infec-
tions (for review, see Karageorgopoulos et al. [36] and
the references therein), in which BG assay sensitivity for
proven or probable IC ranged from 85% [19] to 92%
[37]. Although obtaining multiple samples increased
specificity and PPV of the BG assay for subjects with
acute myeloid leukemia or myelodysplastic syndrome
[16], this may be not the case for ICU patients, for
whom it could be important to explore the performance
of the assay with a single-sample protocol. This protocol
was believed to be potentially closer to the way in which
the assay could be used in ICU clinical settings [35].
Our BG sampling strategy involved the use of a blood
specimen drawn from an arterial line. In the ICU set-
ting, arterial catheters allow continuous real-time blood
pressure monitoring and reduce the need for repeated
punctures for blood gas analysis. Therefore, it was rea-
sonable to assess whether this blood source could be
exploited for microbiological tests, instead of a central
venous catheter (nine of our patients did not harbor this
device). This was, also, in view of a recent study show-
ing no significant statistical difference in rates of con-
tamination between venous and arterial sites of blood
draw [38], at least for patients not particularly vulner-
able to fungal colonization/infection, such as burn
patients. To date, this is the first evaluation enabling use
of the Fungitell kit with sera retrieved from arterial
blood specimens, and, in our opinion, information that
measurements obtained from ei t h e ra r t e r i a lo rv e n o u s
blood samples are equivalent. It could represent a new
and very useful practical aspect.
The use of certain intravenous antimicrobials (for
example, amoxicillin-clavulanic acid) or gauze packing
of serosal surfaces may be a source of false-positive BG
measurements [39]. We detected a high level of BG in
five patients without evidence of fungal infection, one of
whom was undergoing extensive intra-abdominal gauze
exposure following surgery and four were receiving anti-
microbial treatment with b-lactams. However, consider-
ing that 4 of the patients with true-negative BG results
were exposed to surgical gauze and 36 were treated with
b-lactam antibiotics, it is unlikely that a casual relation-
ship between the presence of BG in the blood specimens
and medical interventions exists in our patients. Despite
the wide use of intravenous albumin or immunoglobu-
lins and/or hemodialysis in ICU patients, such medical
treatments did not lead to a false-positive BG elevation
in our patients. Some studies also reported a high num-
ber of false positives in patients with bacteremia, espe-
cially that caused by Gram positive organisms [40,41].
In one study comparing patients with blood cultures
positive for yeast (proven or probable IFI) versus bac-
teremic patients, this appeared to reduce the specificity
of the test and to place its PPV at 52%, but given the
nature of the samples obtained the authors admitted
that BG contamination may have occurred [40]. In
another study analyzing a single specimen in 46 subjects
from ICUs, Digby et al. [41] observed that serum BG
levels were elevated on average in all patients with either
fungal or bacterial infection, even though hemodialysis
as a source of false-positivity may be a factor in these
observations. By contrast, no cross-reactivity of the BG
assay in patients experiencing bacteremias was found in
our study and in the prospective validation assays pub-
lished to date [15-17,34].
Multisite colonization is a predictor for candidemia in
the ICU, especially in combination with other risk fac-
tors reflecting severe disease [4,42]. Thus, IC is highly
improbable if a Candida-colonized critically ill patient
has a CS < 3 [26]. Colonization by fungi was seen to not
raise the concentration of BG [16,34], while BG may
reach the circulation through damaged intestinal or
respiratory mucosa and causes positive test results. In
this case, BG could be the marker of the gut barrier
invasion prior to infection. Of interest, studying a
patient population different from ours but with similar
risk profiles, Senn et al. [17] showed that all of the
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0.50 
0.75 
1.00 
Sensitivity 
0.00  0.25  0.50  0.75  1.00
Specificity 
BG ROC area: 0.98  Candida score ROC area: 0.80 
Colonization index ROC area: 0.63  Reference 
Figure 3 ROC AUC curves of BG, CS, and colonization index for
proven IC cases. [The AUC of BG was significantly higher than
those of CS (P < 0.001) and colonization index (P < 0.001), please
edit this sentence as a footnote].
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patients with gastrointestinal fungal colonization and/or
mucositis who received empirical therapy, suggesting an
occult IC at an early stage. Few studies have performed
direct comparisons of the BG assay, CS, and coloniza-
tion index for identifying patients at risk of development
of IC [26]. In our study, we found that 10 of 13 BG
positive patients with proven IC (true positive) had a CS
≥3a n d7ac o l o n i z a t i o ni n d e x≥0.5, and these findings,
on the one hand, reinforce the discriminatory power of
BG testing between patients with true IC and those
without IC and, on the other hand, suggest its use to
make diagnosis more quickly. However, the not too high
concordance observed warrants additional investigations
whether the three tests can be used as complements to
each other, although an analysis of diagnostic perfor-
mance combining BG assay and CS showed that com-
bined use of the two tests enhanced the sensitivity and
NPV for the diagnosis of IC.
Aside from the low frequency of cases of proven IC,
the experimental design of our study, giving an estima-
t i o no ft h ep r e v a l e n c eo fI F Ii nt h et a r g e tp o p u l a t i o n ,
allowed an assessment of PPV and NPV by use of BG
testing. With a prevalence of fungal infection of 16.8%,
the PPV for the BG test was 72.2%, in spite of a very
high NPV (approximately 99%). Therefore, a strong
diagnostic benefit of BG testing lies in excluding IFI
(and IC), according to that reported earlier [20,35,43],
while an unresolved question about the BG testing
remains the knowledge of factors that could increase
BG levels for reasons other than IFI. Nevertheless, the
small number of subjects studied, leading to broad CI
intervals, should lower the strength of our observations.
Additionally, the pre-test probability of IC in our study
population was high given that 74% of the patients pre-
sented with risk factors for IFI, thus possibly limiting
the generalizability of our data to other patients. How-
ever, a strict but effective patient selection strategy such
as that adopted in this study, if combined with a single-
test approach, may have a major financial impact by
reducing the laboratory costs associated with the use of
this expensive biomarker.
We are aware of the potential limits of BG assay for
detecting fungal infection that would yet balance key
deficiencies in the current culture-based methods, such
as poor sensitivity and delayed turnaround time. A simi-
lar scenario is offered by newer PCR techniques (for
example, SeptiFast; Roche Molecular Systems, Man-
nheim, Germany), though their application to detect and
identify fungal pathogens more rapidly than conven-
tional culture might revolutionize the diagnosis and the
management of sepsis [44]. However, provided an
appropriate laboratory logistics, BG assay results can be
obtained within a few hours, and then more rapidly
than those of PCR techniques, which remain extremely
complex and expensive for a routine microbiology
laboratory.
Conclusions
The BG assay, based on arterial blood sampling, appears
to be useful as a single-point assay for ICU patients
with suspicion of Candida sepsis. In addition, a combi-
nation of CS and BG measurement in this setting may
improve the diagnostic performance and the efficiency
of management. However, this strategy deserves further
study to assess its true value in early detecting ICs and
thus reducing the increased mortality [3] and cost of
ICU stay [45] caused by Candida infections.
Key messages
￿ A timely diagnosis of IC in medical ICU patients with
signs of sepsis is essential to reduce the morbidity and
mortality associated with Candida infection.
￿ The culture-independent serum BG assay may allow
early diagnosis of IC, even when one patient sample is
tested at the onset of the septic syndrome.
￿ The NPV for BG testing in our study population is
nearly 99%, suggesting that a strong diagnostic benefit
of this assay lies in excluding IC.
￿ In all proven-IC cases, a positive BG result was
obtained 24 to 72 hrs before a positive bloodstream cul-
ture result, thus overcoming the delayed turnaround
time of conventional diagnostic methods.
￿ A combined use of BG and CS may improve the
diagnostic performance in ICU patients at risk for Can-
dida sepsis, but additional investigations are needed.
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